Zobrazeno 1 - 10
of 26
pro vyhledávání: '"RS Szor"'
Autor:
LS Abreu, ML Puls, BA Souza, CFM Ferreira, EL Rosa, PHA Moraes, RS Szor, CD Liz, VC Molla, CA Rodrigues
Publikováno v:
Hematology, Transfusion and Cell Therapy, Vol 46, Iss , Pp S113- (2024)
Objetivo: Descrever a importância do acompanhamento do clone HPN em pacientes com anemia aplástica (AA) através de um relato de caso. Métodos: Relato de caso descritivo e observacional, realizado com consentimento livre e esclarecido do paciente.
Externí odkaz:
https://doaj.org/article/abbfc436a1b0492bad14bf4d0cb800ee
Autor:
RAF Machado, ML Puls, BA Souza, CFM Ferreira, EL Rosa, CD Liz, PHA Moraes, RS Szor, VC Molla, C Arrais-Rodrigues
Publikováno v:
Hematology, Transfusion and Cell Therapy, Vol 46, Iss , Pp S112-S113 (2024)
Objetivo: Descrição de caso de tratamento de primeira linha para anemia aplásica muito grave (AAMG) com alentuzumabe como estratégia de linfodepleção. Métodos: Relato de caso descritivo e observacional, com consentimento livre e esclarecido da
Externí odkaz:
https://doaj.org/article/135fc6609c3047ee80cc530b3e3c1e6a
Autor:
TFN Araújo, LPDS Rocha, CF Oliveira, ML Puls, CD Liz, EL Rosa, PHA Moraes, RS Szor, VC Molla, C Arrais
Publikováno v:
Hematology, Transfusion and Cell Therapy, Vol 46, Iss , Pp S334-S335 (2024)
Introdução: A leucemia linfocítica crônica (LLC) é a leucemia mais comum em adultos no mundo ocidental, com média de idade ao diagnóstico de 70 anos, sendo mais prevalente em homens (2:1) e apresentando um risco 6 a 9 vezes maior em pacientes
Externí odkaz:
https://doaj.org/article/b8faaa16a3174335b000885c93b699f7
Autor:
CFM Ferreira, BA Souza, LS Abreu, RAF Machado, EL Rosa, PHA Moraes, VC Molla, RS Szor, CD Liz, C Arrais-Rodrigues
Publikováno v:
Hematology, Transfusion and Cell Therapy, Vol 46, Iss , Pp S459-S460 (2024)
Introdução: A síndrome mielodisplásica secundária a terapia (SMDt) constitui cerca de 10-20% de todas as síndromes mielodisplásicas (SMD) e tende a apresentar sobrevida global inferior devido a características como alterações citogenéticas
Externí odkaz:
https://doaj.org/article/0c529ddb8b8c48a59f6e6a6a8cf3be40
Publikováno v:
Hematology, Transfusion and Cell Therapy, Vol 46, Iss , Pp S511- (2024)
Objectives: Amyloidosis results of tissue deposition of misfolded proteins aggregates, leading to localized or systemic forms. Over 40 proteins are amyloidogenic, the main 2 being immunoglobulin light chain (AL) and transthyretin (ATTR). Mass spectro
Externí odkaz:
https://doaj.org/article/6204336d8c2c47c794986cb9bb9b0b32
Autor:
LS Abreu, ML Puls, RAF Machado, TFN Araújo, CD Liz, PHA Moraes, RS Szor, EL Rosa, VC Molla, CA Rodrigues
Publikováno v:
Hematology, Transfusion and Cell Therapy, Vol 46, Iss , Pp S530- (2024)
Introduction: Cytogenetic abnormalities are crucial for risk stratification and therapeutic decisions in multiple myeloma (MM). The incorporation of 1q+ into the R2-ISS prognostic tool has revealed a new subgroup of very high-risk patients not previo
Externí odkaz:
https://doaj.org/article/12a11954d34f4f2db20229e0e12a6eeb
Autor:
TFN Araújo, LPDS Rocha, CF Oliveira, BA Souza, CFM Ferreira, LS Abreu, RAF Machado, ML Puls, PHA Moraes, EL Rosa, CD Liz, RS Szor, VC Molla, C Arrais
Publikováno v:
Hematology, Transfusion and Cell Therapy, Vol 46, Iss , Pp S1021-S1022 (2024)
Introduction: Adult T-cell Leukemia/Lymphoma (ATL) is a highly aggressive T-cell malignancy that occurs in a proportion of individuals who are long-term carriers of Human T-cell Lymphotropic Virus type 1 (HTLV-1). Allogeneic hematopoietic stem cell t
Externí odkaz:
https://doaj.org/article/12fd82e077ef401c801801b53da685a8
Publikováno v:
Hematology, Transfusion and Cell Therapy, Vol 46, Iss , Pp S1020-S1021 (2024)
Introduction: Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) is the most potent post-remission treatment for Acute Myeloid Leukemia (AML) to reduce relapse rates. However, achieving Complete Remission (CR) and Minimal Residual Disease (MRD
Externí odkaz:
https://doaj.org/article/de8a1f47d0dc4b81b4caba1e96f8fecf
Autor:
EL Rosa, FS Azevedo, CC Justino, AM Fonseca, PHA Moraes, VC Molla, RS Szor, CD Liz, AG Guerra, MM Almeida, GMC Silva, CF Oliveira, TFN Araújo, LPDS Rocha, ML Puls, C Arrais
Publikováno v:
Hematology, Transfusion and Cell Therapy, Vol 46, Iss , Pp S1039- (2024)
Objectives: Second allogeneic Hematopoietic Stem Cell Transplant (HSCT) is the only curative treatment option for patients who relapse after a first transplant for malignant diseases. Previously reported outcomes for this intervention are often disma
Externí odkaz:
https://doaj.org/article/abbd160fcf6549308b4ec8d49a13b356
Autor:
CC Justino, FS Azevedo, EL Rosa, PHA Moraes, AM Fonseca, CD Liz, RS Szor, VC Molla, AG Guerra, CF Oliveira, TFN Araújo, GMC Silva, MM Almeida, LPDS Rocha, ML Puls, C Arrais
Publikováno v:
Hematology, Transfusion and Cell Therapy, Vol 46, Iss , Pp S1036- (2024)
Objectives: Many hematological diseases, such as Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) commonly affect individuals diagnosed in their seventh decade of life or later. Allogeneic Hematopoietic Stem Cell Transplantation (HSCT
Externí odkaz:
https://doaj.org/article/d2b041bf91d84db8a071a033ff23f681